Tenax Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	23.09	23.71	6.79	5.01	5.68	7.58
Research & Development	38.53	32.67	12.71	3.23	5.38	25.15
Total Operating Expenses	61.62	56.39	19.49	8.23	11.05	32.73
Operating Income	-61.62	-56.39	-19.49	-8.23	-11.05	-32.73
Interest Income	3.75	3.82	1.91	0.48	-	-
Interest Expense	-	-	0.02	0.02	-0	-0
Other Non-Operating Income (Expense)	-0.04	-0.03	0	0.06	-0.01	-0.25
Total Non-Operating Income (Expense)	3.71	3.79	1.94	0.57	-0.01	-0.26
Pretax Income	-57.91	-52.6	-17.56	-7.66	-11.07	-32.98
Net Income	57.91	52.6	17.6	7.71	-11.05	-32.47
Net Income to Common	57.91	52.6	17.6	7.71	-11.05	-32.47
Net Income Growth	23.52%	198.82%	128.27%	-	-	-
Shares Outstanding (Basic)	41	39	15	0	0	0
Shares Outstanding (Diluted)	41	39	15	0	0	0
Shares Change (YoY)	74.17%	156.80%	6046.86%	91.74%	-	-
EPS (Basic)	-1.40	-1.34	-1.15	-31.04	-600.71	-31.56
EPS (Diluted)	-1.40	-1.34	-1.15	-31.04	-600.71	-31.56
Shares Outstanding	24.28	9.31	3.42	0.3	0.03	0.02
Free Cash Flow	-38.14	-35.8	-14.81	-5.9	-11.39	-10.86
Free Cash Flow Per Share	-0.92	-0.91	-0.97	-23.76	-87.89	-83.83
EBITDA	-61.62	-56.39	-19.49	-8.23	-10.94	-32.62
EBIT	-61.62	-56.39	-19.49	-8.23	-11.05	-32.73

SEC Filings: 10-K · 10-Q